In vitro activity of GAR-936 against Chlamydia pneumoniae and Chlamydia trachomatis

We evaluated the in vitro activity of GAR-936, a novel glycylcycline antibi otic, against ten isolates of Chlamydia pneumoniae and five strains of C. t rachomatis. Susceptibility testing was done in HEp-2 cells. The MIC(90)s an d MBC(90)s of GAR-936, doxycycline, ofloxacin and clarithromycin against C. pneumoniae were 0.125, 0.25, 0.25 and 0.06 mg/l, respectively. The MICs an d MBCs of GAR-936, doxycycline, ofloxacin and clarithromycin against C. tra chomatis were 0.03-0.125, 0.25, 0.25-0.5 and 0.06 mg/l, respectively. GAR-9 36 had excellent activity against both chlamydial species and may have a po tential role in the treatment of human chlamydial infection. (C) 2000 Elsev ier Science B.V. and International Society of Chemotherapy. All rights rese rved.